Correction to: Scientific Reports https://doi.org/10.1038/s41598-020-71263-9, published online 1 September 2020
In this Article, Figure 1 and its accompanying legend are incorrect. The correct Figure 1 and legend appear below.
A correct version of the original Figure 1. A high proportion of patients may be sensitive to PI3K/PIM inhibition. (A) Venn diagrams demonstrate the percentage of the prostate cancer cohort (TCGA or Ross-Adams, non-metastatic radical prostatectomy patients) that exhibited overexpression of the PI3K pathway, PIM pathway, or both. (B) Disease free survival probability of patients with any pathway upregulation versus no upregulation (left) and after separation into specific pathways (right). P-value was obtained using a Mantel-Cox test. (C) Distribution of Gleason grades within patient population groups. A higher Gleason score (1–5) indicates less well-differentiated prostate tissue and more aggressive disease. A Gleason grade is obtained by adding the Gleason scores of the two most prevalent tissue types in the sample. P-value was obtained using a Chi-square method, and is plotted as a proportion of the patients within each Gleason sum group that fall into each expression group (PIM positive, PI3K positive, both positive or any positive), with colours corresponding to parts A and B.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Luszczak, S., Simpson, B.S., Stopka-Farooqui, U. et al. Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Sci Rep 10, 19870 (2020). https://doi.org/10.1038/s41598-020-76679-x
Published:
DOI: https://doi.org/10.1038/s41598-020-76679-x
